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Purpose: We determined the effects of an innovative 8-week exercise intervention (aerobic, 
resistance and inspiratory muscle training) for patients with mitochondrial disease (MD).  
Methods: Several endpoints were assessed in 12 patients (19–59 years, 4 female) at pre-training, 
post-training and after 4-week detraining: aerobic power, muscle strength/power and maximal 
inspiratory pressure (main endpoints), ability to perform activities of daily living (ADL), body 
composition, quality of life and blood myokines (secondary endpoints).  
Results: The program was safe with patients’ adherence being 94±5%. A significant time-effect 
was found for virtually all main endpoints (P≤0.004), indicating a training improvement. Similar 
findings (P≤0.003) were found for ADL tests, total/trunk/leg lean mass, total fat mass, femoral 
fracture risk and general health perception. No differences were found for blood myokines, 
except for an acute exertional increase in interleukin-8 at post-training/detraining (P=0.002) and 
in fatty acid binding protein 3 at detraining (P=0.002).  
Conclusion: An intervention including novel exercises for MD patients (e.g., inspiratory muscle 
training) produced benefits in numerous indicators of physical capacity, and induced a 
previously unreported shift towards a healthier body composition phenotype.  
 
Key Words: rare diseases; mitochondrial diseases; OXPHOS; VO2peak; resistance training; 
inspiratory muscle training.  
 
  








Mitochondrial disorders are the most prevalent types of neuromuscular disease for which no 
therapy is available. Despite considerable heterogeneity in disease presentation, mitochondrial 
disorders commonly involve skeletal muscle tissue leading to mitochondrial myopathy and poor 
exercise capacity (1). The latter is reflected by low levels of peak oxygen uptake (VO2peak) or 
early onset of anaerobic metabolism (i.e., the so-called ‘anaerobic’ or ‘ventilatory threshold’ 
(VT) (2) or by poor muscle oxygen extraction (as assessed with near-infrared spectroscopy) 
during graded cycle-ergometer/treadmill testing (3,4).  
Several studies have demonstrated the benefits of physical training in this patient group, 
usually in the form of endurance (or ‘aerobic’) exercise performed for a relatively long period 
(~2–12 months), on important outcomes, mainly VO2peak (5-12). This type of exercise 
intervention improves muscle mitochondrial biogenesis and oxidative capacity, as reflected by an 
increase in the activities of citrate synthase (CS) (6,7,10) and respiratory chain complexes (6,10). 
Considerably less work has addressed the effects of a second type of exercise that should also be 
an integral component of any training programme, resistance (‘strength’) exercise (13, 14).  
Muscle-derived molecules, collectively known as ‘myokines’ might account for some of 
the multi-systemic benefits of exercise, especially anti-inflammatory and healthy metabolic 
adaptations such as decreased insulin resistance (15). This is an important consideration in view 
of the high prevalence of physical inactivity coupled to obesity in this patient group (16). No 
study has evaluated exercise effects on the myokine profile of these patients. Moreover, 
controversy exists regarding the effects of exercise interventions on quality of life (QoL), usually 
assessed with the Short Form-36 (SF-36) questionnaire (5,8,9,10-14,16), and scarce data are 
available on how exercise training impacts patients’ ability to perform activities of daily living 
(ADL) (5,13). Myopathy can also affect ventilatory muscles in these patients, which can further 
aggravate their exercise intolerance (18), but no previous study has implemented specific 







inspiratory muscle training (using a threshold-loading device, which can be easily utilized at 
home with little time investment). The effects of exercise interventions on other phenotypes 
related to mitochondrial disorders, muscle and bone mass, remain to be determined. 
We determined the effects of a ‘complete/combined’ exercise intervention consisting of 
innovative aerobic, resistance and inspiratory muscle exercises, performed by patients with 
mitochondrial disease on outcomes indicative of: aerobic power, muscle strength/power and 
maximal inspiratory pressure (PImax) (main endpoints); and ability to perform ADL, body 
composition, QoL and blood myokines (both under resting conditions and in response to acute 
exercise) (secondary endpoints). We hypothesised that our exercise intervention would lead to 
significant improvements, especially in main endpoints.   
 
MATERIALS AND METHODS 
Experimental design and ethics 
This study was approved by the local ethics committee of the Hospital 12 de Octubre (Madrid, 
Spain; approval number: 14/359) and was performed in accordance with the Declaration of 
Helsinki during April 2015–January 2017. All participants provided written informed consent. 
Inclusion criteria were as follows: outpatient (male/female) aged 18–60 years; diagnosed with a 
mitochondrial disorder according to clinical, histomorphologic, respiratory chain and/or genetic 
evidence (19); living in the Madrid area; and having no comorbidity or acute condition 
contraindicating exercise. Study endpoints were assessed at three time-points: baseline (‘pre-
training’), after an exercise intervention (‘post-training’), and after a subsequent 4-week training 
cessation period (‘detraining’). Participants were told not to deviate from their habitual dietary 
habits during the study period. The researchers responsible for assessing participants were 
blinded to time of evaluation. Assessment/training sessions were performed in the rehabilitation 







department (for aerobic exercises) or gymnasium (for strength exercises). The patient study 
design is summarised in Fig. 1.  
Fourteen patients originally agreed to participate but two of them withdrew during the 
first 3 weeks (one due to urine infection and the other one due to personal reasons). The main 
clinical/diagnostic characteristics of the patients who completed the study (n=12) are shown in 
Table 1; 46% were overweight [Body Mass Index (BMI)=25–29.9 kg·m
-2
], 8% obese (BMI >30 
kg·m
-2




The intervention lasted 8 weeks and included three weekly sessions (Monday, Wednesday and 
Friday; total number of planned sessions, 24; session duration, 60–90 min). Each session was 
supervised by experienced fitness instructors (one per participant) and included three main 
components: aerobic, muscle resistance (‘strength’) and specific inspiratory muscle training. 
Make-up sessions (on a Tuesday/Thursday) were allowed if a planned session was missed. To 
determine the adherence to training, we considered a session completed when ≥90% of the 
prescribed exercises were successfully performed (20).  
Aerobic training. Each session started with aerobic training on a cycle-ergometer (Ergoselect 
100P, Ergoline, Bitz, Germany). Aerobic exercise was preceded  by an initial 10 min warm-up 
and a final 5 min cool-down period; the central component lasted only 20 min and was 
performed following a low-volume ‘high intensity interval training’ (HIT) protocol (21), where 1 
min bouts at a target load were interspersed with recovery periods of the same duration. 
Although one possibility is to use 30-second, ‘all-out’ (i.e., Wingate) repetitions, this might not 
be safe, tolerable or appealing for some individuals, such as patients (21). Thus, a more practical 
model of low-volume HIT that is still time-efficient (as it can be performed over 20  min) while 
also having wider application to different populations including patients, consists of 10 × 1 min 
work bouts at a constant-load, very high intensity (∼90% of maximal heart rate), interspersed 







with 1 min of recovery (21). Owing to the poor baseline physical condition of our participants 
and to the fact that HIT has not been previously applied to this patient population, we did not 
target high intensities until the second half of the program. Thus, the target power output (watts) 
was gradually and individually increased during the program as follows: weeks 1–2, 65% of 
peak power output (PPO) reached during the baseline cycle-ergometer test until exhaustion (see 
below); weeks 3–4, 75% of PPO; weeks 5–6, 85% of PPO; weeks 7–8, 90–100% of PPO. The 
load for recovery periods was kept below 65% of PPO.  
Resistance training. This followed the aerobic training and included a three-time circuit of 
exercises involving large muscle groups and performed with specific weight training equipment 
(Gervasport, Pleven, Bulgaria) in the following order: leg and bench press, leg extension, lateral 
pulldown and abdominal crunches. Initial loads for each exercise were individually determined, 
using values of 6–7 in the Borg 1–10 scale of perceived exertion. The rate of load increases was 
also set individually as follows: when the patient reported a score <6 for a given exercise in two 
consecutive sessions, the corresponding load was increased (with the premise that the score for 
the new load=6–7). The number of repetitions for each exercise was decreased with 
corresponding increases in load (kg) as follows: 15 (weeks 1–4) and 7–8 repetitions (weeks 5–8).  
Inspiratory muscle training. This included two daily sessions (morning and evening, all at the 
patient’s home except for Monday-Wednesday-Friday where the evening session was performed 
inhospital after the aforementioned resistance training), 6 days/week (Monday–Saturday). Each 
of the two daily sessions consisted of 30 inspirations through a specific pressure-load device 
(Powerbreathe® Classic Medium Resistance, Powerbreathe International Ltd., Southam, UK) 
against 40% of PImax (session duration ~5 min) (20). Paticipants’ PImax was reassessed by us at 
the beginning of each week to adjust the weekly load accordingly. 
 
 








All assessments were consistently performed over a 1-week period in the following days and 
order at each of pre-, post- and detraining, respectively, after familiarisation with the equipment 
and tests (Thursday and Friday): first assessment day (Monday of the next week), venous blood 
drawing, cycle-ergometer test followed by post-exercise blood drawing, and distribution of QoL 
questionnaires; second day (Wednesday), strength tests followed by functional tests of ADL, and 
PImax test; and third day (Thursday or Friday), body composition analysis. In order to rule out a 
potential effect of changes in patients’ levels of habitual physical activity (PA) on study 
outcomes, during the week prior to the aforementioned assessments at pre-, post- and detraining, 
we determined PA objectively, using a triaxial accelerometer (GT3X monitor device, Actigraph; 
Pensacola, FL) (22). For each study participant, a minimum of 5 days’ monitoring (including 2 
weekend days), and a minimum of 10 hours/day of complete accelerometry were considered 
necessary. Data were analyzed using ActiLife5 LITE software (Actigraph, Pensacola, FL). We 
determined average intensity (counts/min) by dividing the sum of the total counts per pre-defined 
epoch (15 seconds) for a valid day by the number of minutes of wear time in that day across all 
valid days. Thereafter counts were converted to average daily time engaged in moderate-
vigorous PA (22).   
 
Main endpoints 
Aerobic power. Aerobic exercise testing was performed on a cycle-ergometer, following a ramp-
like protocol (workload increases of 1 watt every 6 s (averaging 10 watts/min) starting from an 
initial load of 0 watts, with a pedal cadence of 60–70 rpm throughout the test). Gas-exchange 
variables were collected breath-by-breath with an automated metabolic cart (Quark CPET, 
COSMED, Rome, Italy). The VO2peak and the peak pulmonary ventilation rate (VEpeak) were 
computed as the highest value of these two variables obtained for any 20-s period during the 







tests. Two important physiological indicators of submaximal aerobic power, VT and respiratory 
compensation point (RCP), were detected using previously defined criteria (23).  
Muscle strength/power. We assessed upper/lower-body muscle power with bench/leg press tests 
using the same equipment as for training, connected to a linear encoder (Power Encoder, 
Smartcoach Europe, Stockholm, Sweden). This methodology has proven valid to determine 
muscle force (N) and power (W) (24) and has been recently applied by us for assessing patients 
with different types of myopathy (20,25). Patients performed one set of three repetitions for each 
exercise at the maximum possible speed; each set was followed by a recovery period of 60–90 s. 
The load (or ‘resistance’) was increased by 5 or 10 kg (leg press) and by 2 kg (bench press) in 
each successive set. Because power is the product of force and velocity, it initially increases with 
resistance and then decreases when the resistance causes a substantial decrease in velocity. Thus, 
the test is stopped when the decrease in velocity is so pronounced that it also causes a decrease in 
average muscle concentric power. An advantage of this test is that it ends with a submaximal 
load, thereby avoiding major/haemodynamic problems. We recorded the highest value of 
average power (watts) and load (kg) in the concentric-propulsive phase, which typically 
coincides with the start of a decline in this variable together with the occurrence of the highest 
value of average force (newtons) (20, 25).  
Maximal inspiratory capacity. We measured participants’ PImax at the residual volume using a 
mouth pressure metre (Micro Medical Inc., Chatham, Kent, UK) (20). 
Secondary endpoints 
Functional capacity during ADL. Walking capacity was evaluated with the six-minute walking 
distance test (6MWD) test in accordance with established standards (20). Mobility was assessed 
with the timed up and go test (TUG) and 15-step stair tests (26). 
 







Body composition. Total and regional body composition was assessed by dual energy x-ray 
absorptiometry (DXA) (Hologic Serie Discovery QDR, Physician’s Viewer, APEX System 
Software Version 3.1.2. Bedford, MA, USA) as described (27). An additional examination was 
conducted to estimate bone mass and femoral T-score (number of standard deviations above or 
below the young adult mean bone mineral density) at the proximal region of the femur. Femoral 
T-scores were calculated using the manufacturer’s reference values based on the revised National 
Health and Nutrition Examination Survey III reference data (27). Patients were also compared 
with a sex and age-matched healthy control group (21 men and 12 women, age 45.7±2.0 years) 
previously assessed by us with the same equipment.  
QoL. We used the Spanish version of the SF-36 questionnaire (version 2) to assess patients’ 
health-related QoL (28).  
Blood variables. Twenty myokines/cytokines were assessed in plasma samples before (‘basal’) 
and after aerobic power tests using the MILLIPLEX® MAP Human High Sensitivity T Cell 
Magnetic Bead Panel and the MILLIPLEX® MAP Human Myokine Magnetic Bead Panel with 
Luminex® Technology on a MAGPIXTM instrument (EMD Millipore Corporation, Billerica, 
USA). Basal plasma levels of creatine kinase (CK) [laboratory reference values <190 U/L (men) 
and <170 U/L (women)], creatinine [reference <1.2 mg/dL (men) and <0.9 mg/dL (women)] and 
lactate (reference 0.5–2.2 mmol/L) were also measured using a Cobas C spectrophotometer 
(Cobas® 8000 modular analyser series, Roche Diagnostics, S.L., Spain).       
Statistical approach  
We compared endpoint values over time with the non-parametric Friedman test. We also 
compared acute changes (pre- vs. post-exertion) in myokines at each of the three study time-
points with the Wilcoxon test. Finally, DXA variables were compared between patients and 
controls with Mann–Whitney’s U test. To minimise the risk of statistical error type I (given the 
large number of endpoints), analyses were corrected for multiple comparisons with the stringent 







Bonferroni method in which the threshold P-value is obtained by dividing 0.05 by the number of 
comparisons; further, post hoc paired comparisons were performed only for those endpoints 
showing a significant time effect.  
 
RESULTS 
Valid accelerometry data in each of the three time points were obtained from 7 patients. 
Mean(±SEM) levels of MVPA did not differ (P=0.8426) between pre- (56±20 min/week), post- 
(56±21 min/week) or detraining (45±29 min/week). Vigorous PA was virtually absent in all 
individuals in the three points of assessment. 
Adherence and safety 
Mean adherence to the programme was 94±5% (range: 83–100). Main reasons for missing 1+ 
sessions were family (n=5 sessions) or work (n=4) obligations, medical visits (n=1) or minor 
health issues temporarily disabling exercise (n=7, e.g., upper respiratory tract infection, 
migraine). No health issues other than the expected muscle discomfort were noted. In two 
subjects, the 15 repetitions that were originally planned for strength exercises during weeks 1–4 
were divided in two sets of 7–8 repetitions to attenuate muscle pain.  
Main endpoints  
Peak values of heart rate (161±6, 164±6 and 161±7 beats/min at pre-, post- and detraining, 
respectively, P=0.242 for time effect) and respiratory exchange ratio (1.18±0.04, 1.18±0.02, and 
1.23±0.03, P=0.368) reached by the participants in the aerobic power tests did not differ over 
time which, besides indicating a comparable level of effort, suggests that patients performed a 
maximal effort in the three assessments. A significant time effect was found for all endpoints 
indicative of aerobic power, muscle strengh and inspiratory muscle power (all P≤0.004) except 
for VO2 at the RCP relative to muscle mass (P=0.006), indicating a consistent training 
improvement (Table 2). Statistical significance was also reached for numerous endpoints in 







paired post hoc comparisons of pre- vs. post-training values. Importantly, some training 
improvements were not completely lost after detraining, with several values at detraining 
remaining significantly higher than at pre-training (P≤0.004). All main endpoints showed the 
same individual response (i.e., training-induced improvement) for virtually all patients (see 
Figure, Supplemental Digital Content 1, Individual data for patients’ main endpoints, 
http://links.lww.com/MSS/B189). 
Secondary endpoints 
A significant time effect (P≤0.003) was found for all outcomes indicative of functional capacity 
in ADL, total/trunk and leg muscles’ muscle mass, total fat mass, femoral fracture risk (T-score) 
and general health perception in the SF-36 questionnaire. Similar to the main outcomes, this 
indicated a training-induced improvement (which for fat mass and T-score was reflected in a 
decrease in mean values) followed by a subsequent loss, at least partially, of such improvements 
after detraining (Table 3). In post hoc analyses, we found a significant improvement at post- 
compared with pre-training for all the functional tests as well as for total lean and leg muscle 
mass (all P≤0.003). Further, detraining values of 6MWD and 15-step stair tests, and total lean 
mass remained significantly higher than pretraining values (P≤0.003). For ADL tests and DXA 
variables, virtually all patients showed the same individual response (i.e., training-induced 
improvement; see Figure, Supplemental Digital Content 2, Individual data for patients’ 
secondary endpoints, http://links.lww.com/MSS/B190). Furthermore, lean mass was significantly 
lower in patients than in controls (see Table, Supplemental Digital Content 3, Results of dual 
energy x-ray absorptiometry in mitochondrial disease patients and age and gender-matched 
healthy controls, http://links.lww.com/MSS/B191). 
 
 







No significant time effect was found for the basal levels of blood variables (all P>0.002) 
(Table 4). A significant acute exertional increase was found only for interleukin-8 (IL8) at post- 
and detraining (both P=0.002) and for fatty acid binding protein 3 (FABP3) at detraining 
(P=0.002) (Table 4). 
 
DISCUSSION 
The main finding of our study was that, despite its relatively short duration (8 weeks), a 
‘complete’ and innovative exercise intervention including aerobic, resistance and specific 
inspiratory muscle exercises performed by patients with mitochondrial disorders produced 
significant benefits in numerous indicators of their physical capacity, including aerobic power, 
muscle strength and inspiratory muscle power. It also improved patients’ ability to manage ADL 
and their general health perception. The training programme also induced a shift towards a 
healthier body composition phenotype, with increased and decreased muscle and fat mass, 
respectively. Importantly, despite the heterogeneity in clinical profiles, these improvements were 
corroborated in virtually all patients individually. Further, many of the training improvements 
were partly retained after detraining. Our intervention was also safe and well tolerated by the 
patients: no major health issues, no significant increases in muscle damage (CK levels) and no 
alterations in renal function (creatinine) were found. To the best of our knowledge, this is the 
first study to use such an ‘integrative’ training approach and to show benefits in essentially all of 
the functional endpoints we tested, including also improvements in important novel outcomes, 
muscle mass and bone fracture risk. 
Peak aerobic power levels are usually poor in mitochondrial disorders (1,4-6). The 
VO2peak levels varied widely among our patient cohort, which is likely attributable to the 
variability in the magnitude of OXPHOS impairment in this patient group (1). Nevertheless, 
before starting the training programme, the majority (75%) of patients had a VO2peak level <25 
















 for most humans). The finding that mean VO2peak approached 8 MET is 
clinically relevant because this is the minimum threshold for optimal health, above which the 
risk for all-cause mortality is significantly reduced (29).  
 Importantly, VO2peak also increased significantly after training when normalised to leg 
muscle mass, which was most involved during the exercise mode of leg pedaling used here both 
for aerobic power assessment and aerobic training. This suggests an improved ability of the 
trained muscle tissue to extract and use O2 during exercise, which is considered a major limiting 
factor of the VO2peak that can be reached by patients (5,11,30). Our hypothesis of increased 
patient muscle aerobic power after training is consistent with previous studies reporting 
improved endothelial function, mitochondrial biogenesis and oxidative capacity (6–11,17), as 
well as increased peak oxygen extraction (as assessed by near-infrared spectroscopy) in the 
muscle tissue of trained patients (12). Unfortunately, we were not authorised by our ethics 
committee to collect muscle biopsies from the patients.  Our observations of significant 
improvements in VO2peak through training is in agreement with previous intervention studies of 
similar or longer duration that have focused on aerobic exercise (5–12). The success of our 
training programme despite its relatively short duration might be attributable to the low-volume 
HIT protocol we used, at least for the second half of the intervention, where participants 
performed ~10 repetitions of 1-minute intervals per session, at ~80% (weeks 5–6) and 90–100% 
of peak watts achieved during the baseline cycle-ergometer test (weeks 7–8). Indeed, growing 
evidence suggests this type of training stimulates physiological adapations (e.g., VO2peak 
increases) comparable with moderate-intensity continuous training despite a lower time 
commitment and exercise volume (21,31). Our findings are also important in practical terms 
given that 'lack of time' remains the most commonly cited barrier to regular exercise 
participation among westerners (21). By contrast, previous studies have used interventions of 







continuous exercise during longer bouts but at lower intensities, such as 30 min at 70% of peak 
watts (13), 30–45 min at 65–80% of maximal heart rate (10-12), or 30 min at 70–80% of VO2peak 
(5–7). Of note, here we chose to use the term ‘VO2peak’ instead of maximal oxygen uptake 
(‘VO2max’). A second, constant work rate test performed at ~110% of the work rate achieved on 
the initial ramp test would have served as a validation tool to assess actual VO2max levels (32). 
This validation method might be incorporated for the assessment of mitochondrial disease 
patients in future training studies. 
 Patients with mitochondrial disorders often show a deteriorated maximal inspiratory 
capacity, as  manifested by a low PImax (18). In this regard, the mean baseline values of PImax in 
our patients (79±11 cmH2O) were only slightly (+3.8%) higher than those we recently reported 
using the same method in patients of a very similar mean age (~46, vs. 47 years here) suffering a 
devastating disease, pulmonary arterial hypertension, which typically provokes marked exercise 
intolerance together with frequent dyspnea and also myopathy affecting ventilatory muscles (20). 
Yet, not only PImax (+29%, P<0.001), but also another indicator of muscle ventilatory capacity, 
VEpeak, showed remarkable increases with training (+25%, P<0.004). Two patients (#2 and #12, 
Table 1) required non-invasive nocturnal ventilatory support (with Bilevel Positive Airway 
Pressure, biPAP). Although after the training program they both reported feeling less ventilation-
limited during daily living, the biPAP was still kept at night for safety purposes. Further, any 
improvement in respiratory muscle capacity as the one shown here is of potential medical 
relevance because in the long-term, respiratory failure is a main cause of death among adults 
with mitochondrial disorders (33).  
Patients with  mitochondrial disorders have high blood lactate levels at rest and especially 
during exercise, even of submaximal intensity, as a consequence of OXPHOS dysfunction (1). In 
this regard, we also found a significant training-induced improvement in two important 
indicators of submaximal exercise capacity, the VT (also referred to as the ‘anaerobic threshold’) 







and the RCP (also known as ‘second VT’). Previous studies have also found an increase in the 
VT with training in this patient group (5,13), but ours is the first study to assess training effects 
in the RCP. While the VT represents the first increase in pulmonary ventilation that is 
proportional to the increase in CO2 output generated by the HCO3
-
 buffering of lactic acidosis, 
the RCP represents a higher work intensity at which blood lactate accumulation increases 
considerably (i.e., production exceeds clearance) and is accompanied by an additional 
hyperventilation in an attempt to buffer increasing blood acidosis (23). Therefore, the increments 
in VT and RCP provoked here were likely mediated by: (i) a higher ability to buffer lactic 
acidosis, and (ii) a higher ability of working muscles to rely on aerobic metabolism, as reflected 
by the finding that VO2peak normalised to leg muscle mass increased with training. 
We used a novel, practical approach to assess the effects of strength training on the ability 
of muscles to produce power by studying the force-velocity curve, allowing the patients to avoid 
performing maximal efforts and the Valsalva maneuver, and therefore limiting the risk of 
adverse events (as opposed to ‘classical’ ‘one-repetition maximum’ weight lifting exercises). 
Moreover, compared with conventional one-repetition maximum tests, muscle power 
improvements have more direct transference into patients’ ability to perform ADL (e.g., standing 
from a chair, stair climbing) (20). This was indeed reflected in the training-induced improvement 
we found for all outcomes indicative of functional capacity during ADL (6MWD, TUG and 15-
step stair tests) in our patients, demonstrating that ADL was better tolerated after training.  
The increments in strength/muscle power levels were accompanied by improvements in 
muscle mass measured by DXA. No study has assessed exercise training effects on the muscle 
mass in this patient group; yet, it is a potentially important issue as our patients showed 
significantly lower total lean mass (~18%) than their healthy peers. Thus, the training 
improvement in total lean mass is of special relevance, particularly the higher values at the lower 
extremities. This training effect remained after the detraining period. The phenotype of patients´ 







muscle tissue was likely changed with resistance training towards hypertrophy A previous study 
has reported that strength training increases the number of satellite cells (as a result of increased 
muscle damage) and of intermediate muscle fibres, while decreasing the number of cytochrome c 
oxidase-deficient fibres (14). Although the mechanisms involved in this process remain to be 
clearly elucidated, Murphy et al. proposed that the activation of quiescent mitotic cells by 
strength training results in the shifting of normal mitochondrial templates to mature muscle and 
restoration of a normal mitochondrial genotype and phenotype (14). However, a similar 
proportion of mitochondrial DNA (mtDNA) mutations (single large-scale deletions) has been 
reported in satellite cells and mature muscle of patients with mitochondrial disorders (34). 
Unfortunately, the fact that we did not perform muscle biopsies precluded assessing a potential 
training effect on mtDNA mutational load at the muscle tissue level. 
Training-induced gains in muscle mass were also accompanied by a reduction in fat mass, 
and consequently a healthier body composition phenotype. While keeping in mind the limitation 
that we did not assess potential dietary effects on the body composition changes observed during 
the study, this is also an important finding given that many of these patients are at high risk of 
metabolic conditions such as obesity and type 2 diabetes (16,35–37), or impaired glucose 
tolerance and diminished insulin-stimulated glucose influx to skeletal muscle and adipose tissue 
(36). An additional novelty of our study was the finding that exercise training decreased the risk 
for femoral fractures (T-score), which is also clinically relevant in light of the fact that 
mitochondrial disorders are often associated with endocrine conditions that can adversely affect 
bone mass (diabetes mellitus, insulin resistance/glucose intolerance, hypoparathyroidism, renal 
tubular acidosis, chronic renal insufficiency and gastrointestinal disease) (38). Interestingly, one 
of our patients was reclassified from osteoporotic to osteopenic after the training period (T-score 
of -2.5 and -2.3, respectively). The finding that 7 patients were classified as having osteopenia or 
osteoporosis at the beginning of the study and the proposed link between mitochondrial 







dysfunction and a bone phenotype (38) further support the need to implement exercise 
interventions such as those used here in this patient group.  
Skeletal muscle can act as an endocrine organ, especially during contractions, by 
releasing molecules that are collectively known as ‘myokines’ (mainly proteins and peptides) 
into the bloodstream (15). Myokines account for some of the beneficial effects of exercise, such 
as anti‐inflammatory effects, or healthy metabolic adaptations (e.g., decreased insulin 
resistance). In this regard, patients with mitochondrial disorders can present high basal 
concentrations of several pro-inflammatory cytokines (such as TNFα) (36). Accordingly, we 
evaluated the effects of exercise training on basal myokine levels and found no statistically 
significant differences. By contrast, a significant acute increase in IL8 was found at post- and 
detraining, and FABP3 at detraining. Previous research on healthy adults has reported an 
increase in circulating levels of IL8 after an exercise bout (39). Similarly, IL8 receptor levels are 
elevated in the working skeletal muscles of healthy individuals (15) and in patients with 
mitochondrial disorders after an acute exercise bout (36), with IL8 receptor-mediated signaling 
potentially stimulating local angiogenesis (15). A stimulating effect of IL8 on angiogenesis after 
acute exercise might be mediated by CXC receptor 2 signalling, which in the longer-term may 
increase muscle capillarity (15). In a previous study, capillary density increased after 12-month 
aerobic training in four patients with different mtDNA mutations and high mtDNA mutational 
load (7), although the underlying mechanism remains unknown. However, the same authors 
found a training-induced decrease in capillary density after 12-week aerobic training (6). Clearly, 
more research is needed to examine the effects of exercise on muscle capillarisation in patients 
with mitochondrial disorders and to determine whether IL8-related pathways are involved. Our 
data on FABP3 are in agreement with a previous study in healthy individuals where a single bout 
of endurance cycle-ergometer exercise provoked an increase in FABP3 expression in vastus 
lateralis muscle (40). FABP3 facilitates the cytoplasmic transport of fatty acids through 







intracellular membranes and provides the primary means for energy production in working 
skeletal muscle together with carbohydrates (40). Future studies might determine if longer 
exercise training interventions are needed to elicit significant changes in the myokine blood 
profile. 
Besides unavailability of patients’ muscle biopsies due to ethical constraints, a main 
limitation of our study was that we did not perform a randomised controlled trial on patients. 
This is partly compensated by the fact that we assessed patients at three time points (including 
detraining), thereby preventing subject bias as the same subjects were used as their own controls. 
In addition, the exercise intervention did not have a beneficial impact on patients’ MVPA levels 
after it had ended (i.e., detraining period). Nevertheless, our study has several strengths. It is the 
first to use an ‘integrative’ training approach in this patient group. Other strengths were: the 
myriad benefits obtained, the novelty of several endpoints (such as bone and muscle mass) and 
of our training methods, including low-volume HIT, ‘specific’ resistance training and inspiratory 
muscle exercises. Concerning the latter method, this was easy to perform, little time-consuming, 
and it induced a significant improvement in inspiratory muscle capacity. Finally, we minimised 
type I statistical error by adjustment for multiple comparisons. 
 
In conclusion, an 8-week ‘complete’ exercise intervention, produced benefits in 
numerous indicators of physical capacity in patients with mitochondrial disorders, as well as a 
shift towards a healthier body composition phenotype, with increased and decreased muscle and 
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1 M 59 
CPEO, ptosis and bulbar weakness  
(dysphagia and dysphonia) 
Normal (<200) COX-, RRF N/A 
Multiple mtDNA deletions 
TWNK: c.1361T>G, p.Val454Gly, heterozygous
*
 
2 F 53 
Progressive myopathy with prominent ataxia, 
facial and respiratory muscle weakness* 
400 COX-, RRF Normal Multiple mtDNA deletions 
3 M 57 Fatigue and exercise intolerance 500–1 000 COX-, RRF 
CI, CIII and CIV 
deficiency 
Multiple mtDNA deletions, 
POLG: c.2573C>T, p.Thr858Ile* 
4 F 40 
MELAS, seizures, exercise intolerance, 
diabetes mellitus and hearing loss 
300 COX-, RRF N/A 
MTT1: m.3243A>G,  
89% heteroplasmy in skeletal muscle 
5 M 41 Exercise intolerance 1 200 COX-, RRF N/A 
MTTN: m.5692T>C 
73% heteroplasmy in skeletal muscle;  
6 M 19 CPEO, exercise intolerance and migraines 400 COX-, RRF Normal 
Single large-scale mtDNA deletion 
: 4.8 kb; 60% heteroplasmy in skeletal muscle;  
7 M 50 CPEO and exercise intolerance 300 COX-, RRF N/A 
Single large-scale mtDNA deletion; : 4.0 kb 
78% heteroplasmy in skeletal muscle 
8 M 52 
Bilateral optic neuropathy, hearing loss, 
axonal sensory polyneuropathy and ataxia 
Normal (<200) Normal CI deficiency 
Multiple mtDNA deletions 
OPA1: c.1189G>A, p.Lys397Glu, 
heterozygous** 
9 M 39 Retinitis pigmentosa and migraines Normal (<200) N/A N/A 
MTATP6: m.8993T>G,  
81% heteroplasmy in blood 
10 F 35 
CPEO with asymmetrical ptosis and 
exercise intolerance 
400 COX- Normal 
Single large-scale mtDNA deletion. : 5.7 kb 
34% heteroplasmy in skeletal muscle 
11 F 57 CPEO and exercise intolerance Normal (<200) COX-, RRF Normal. CS  
Single large-scale mtDNA deletion 
: 4.8 Kb; 40% heteroplasmy in skeletal muscle 
12 M 58 
Progressive myopathy, bulbar weakness and 
respiratory failure* 
400 COX-, RRF Normal 
Multiple mtDNA deletions 
TK2: c.604_606del, p.201-202del, homozygous 
 
Abbreviations: CI, CIII, CIV, mitochondrial respiratory chain complex I, III and IV, respectively; CK, creatine kinase; COX-, fibres deficient in cytochrome c oxidase; CPEO, chronic 
progressive external ophthalmoplegia; CS, citrate synthase; F, female; ID, identification; M, male; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 
syndrome; mtDNA, mitochondrial DNA; N/A, not available; OPA1a , optic atrophy 1 (autosomal dominant) gene (ref NM_130837); RRF, ragged-red muscle fibres; TK2, thymidine kinase 2 
gene (ref NM_004614); TWNK, Twinkle helicase gene (ref NM 021830.4);. 
Symbols: : Estimated size of single mtDNA deletion on Southern blot;* required non-invasive nocturnal ventilatory support (with Bilevel Positive Airway Pressure, biPAP); **Novel 
unpublished mutation in a nuclear gene involved in maintenance of mtDNA defect: family segregation, population variant frequency in ExAC, EVS and 1000genomes databases, and 
pathogenicity scores of several predictors of missense variants (SIFT, Polyphen2, CADDPhred, M-CAP among others) suggested the variant was pathogenic.  
  
















Data are mean ± SEM. Significant p-values are in bold -threshold p-value was set at 0.004 (=0.05/14). 
Abbreviations: PImax, maximal inspiratory pressure; PPO, peak power output; RCP; respiratory compensation 





















post hoc comparisons 
 
t0 vs. t1 
 
t1 vs. t2 
 
t0 vs. t2 
 
 
Aerobic power, peak values 
       
PPO (W)  98 ± 11 123 ± 13 112 ± 12 < 0.001 0.003 0.003 0.004 
PPO/legs muscle mass (W kg
-1) 15 ± 1 18 ± 1 17 ± 1 < 0.001 0.005 0.008 0.007 
VO2peak [mL· kg (of whole body mass)
-1 min-1] 22.1 ± 1.8 25.8 ± 1.8 24.2 ± 1.9 < 0.001 0.003 0.008 0.003 
VO2peak  [mL· kg (of legs’ muscle mass)
-1 min-1] 229 ± 13 259 ± 11 243 ± 15   0.003 0.005 0.028 0.037 
VEpeak (l
 min-1) 65 ± 7 87 ± 9 78 ± 9   0.004 0.004 0.037 0.016 
 
Aerobic power, VT 
       
VO2 [mL·kg (of whole body mass)
-1 min-1] 14.0 ± 1.2 19.1 ± 1.5 16.9 ± 1.5 < 0.001 0.003 0.003 0.003 
VO2 [mL· kg (of legs’ muscle mass)
-1 min-1] 152 ± 7 195 ± 9 170 ± 12   0.002 0.005 0.013 0.059 
 
Aerobic power, RCP 
       
VO2 [mL·kg (of whole body mass)
-1 min-1] 17.8 ± 1.5 23.0 ± 2.2 21.1 ± 2.0 < 0.001 0.003 0.033 0.004 
VO2 [mL· kg (of legs’ muscle mass)
-1 min-1] 186 ± 10 230 ± 16 215 ± 15   0.006 - - - 
 
Strength tests, leg press 
              
Peak power (W) 281 ± 42 456 ± 72 473 ± 88 < 0.001 0.002 0.155 0.003 
Peak power [W·kg (of legs’ muscle mass)-1] 41 ± 5 65 ± 8 60 ± 8 < 0.001 0.003 0.155 0.003 
 
Strength tests, bench press 
       
Peak power (W) 127 ± 31 190 ± 41 150 ± 29 < 0.001 0.003 0.021 0.182 
Peak power [W·kg (of arms’ muscle mass)-1]  58  ± 12   79 ± 13 62 ± 10   0.002 0.005 0.028 0.386 
 
Inspiratory muscle strength 
       
PImax (cmH2O) 79 ± 11 112 ± 15 107 ± 15 < 0.001 0.002 0.084 0.002 








                    Table 3. Results of patients’ secondary endpoints by training status 
 
Data are mean ± SEM. Significant P-values are in bold and threshold P-value was set at 0.003 (=0.05/20). Abbreviations: 6MWD, 6-





















post hoc comparisons 
 
t0 vs. t1 
 
t1 vs. t2 
 
t0 vs. t2 
 
 
Functional tests  
       
6MWD (m) 464 ± 26 562 ± 28 530 ± 26 < 0.001 0.002 0.010 0.002 
TUG test (s)  5.7  ± 0.5  4.6 ± 0.4   5.1 ± 0.5 < 0.001 0.002 0.013 0.006 
15-step stair test (s)  38.7 ± 4.1 27.3 ± 2.8 29.7 ± 2.8 < 0.001 0.002 0.015 0.002 
 
DXA, lean mass 
       
Total lean mass (kg) 41.4 ± 2.8 42.5 ± 2.8 42.7 ± 2.8 < 0.001 0.003 0.182 0.003 
Trunk lean mass (kg) 20.9 ± 1.3 21.5 ± 1.3 21.6 ± 1.3 0.003 0.006 0.374 0.006 
Leg muscle mass (mean) (kg)   6.6 ± 5.3  6.8 ± 5.2   6.8 ± 5.1 0.001 0.003 0.594 0.006 
Arm muscle mass (mean) (kg)   2.0 ± 0.2  2.1 ± 0.2   2.1 ± 0.2 0.009 
   
 
DXA, fat 
       
Total body fat mass (kg) 24.3 ± 2.1 23.4 ± 2.1 23.0 ± 2.1 0.001 0.010 0.050 0.021 
 
DXA, bone 
       
Femoral neck bone mineral density 
(g/cm2) 
0.75 ± 0.14 0.76 ± 0.14 0.75 ± 0.14 0.125       
Femoral fracture risk (T-score) -1.2 ± 0.3 -1.1 ± 0.3   -1.2 ± 0.3 0.001 0.026 0.136 0.918 
 
Quality of life, SF-36     
        
Total physical component  34 ± 3 43 ± 3 40 ± 3  0.009     
Total mental component  46 ± 3 46 ± 3 43 ± 3 0.038 
 
  
Physical function 54 ± 9 68 ± 8 67 ± 7 0.008    
Physical role 51 ± 8 64 ± 9 57 ± 9 0.043    
Pain  41 ± 7 63 ± 9 50 ± 6 0.027    
General health 32 ± 6 47 ± 7 39 ± 7 0.001 0.008 0.007 0.044 
Vitality 34 ± 7 47 ± 8 44 ± 7 0.159    
Social function  67 ± 8 79 ± 7 66 ± 9 0.032    
Emotional role 76 ± 7 78 ± 7 69 ± 6 0.123    
Mental health 63 ± 6 65 ± 5 64 ± 6 0.412    








Table 4. Results of blood variables by patients’ training status  
 
Data are mean ± SEM. Significant P-values are in bold -threshold P-value was set at 0.002 (=0.05/23). Acute change = value after maximal cycle-ergometer test minus value 
before maximal cycle-ergometer test. Abbreviations: BDNF, brain-derived neurotrophic factor; CK, creatine kinase; EPO, erythropoietin; FABP3, fatty acid binding protein 
3; FGF21, fibroblast growth factor 21; FSTL1, follistatin-like 1 (also known as TSC-36); IL, interleukin; LIF, leukemia inhibitory factor; SPARC, secreted protein acidic and 






    
Acute change 
   
 
















Myokines/cytokines (pg/mL)                
Apelin   117 ± 43       153 ± 39  75 ± 22 0.030  -18 ± 11 0.419 -39 ± 27 0.102 22 ± 12 0.102 
BDNF     1,269 ± 340    1,040 ± 159   689 ± 123 0.014    -367 ± 317 0.206  157 ± 239 0.206 390 ± 216 0.096 
EPO  2,239 ± 352    2,381 ± 345 1,634 ± 212 0.030    -362 ± 199 0.414 -309 ± 144 0.102 317 ± 227 0.102 
FABP3  1,588 ± 284    1,297 ± 190 1,511 ± 299 0.741   140 ± 86 0.058 211 ± 70 0.058  153 ± 50 0.002 
FGF21   43 ± 7 48 ± 6   52 ± 10 0.565    -8 ± 3 0.059   4 ± 4 0.257    -8 ± 10 1.000 
Fractalkine  297 ± 75 307 ± 70    221 ± 48 0.513    -20 ± 28 0.414  -33 ± 31 0.414    40 ± 36 0.414 
FSTL1     5,685 ± 1 517   7,134 ± 1,317 3,443 ± 640 0.074  -1,075 ± 784 0.180 -2,297 ± 751   0.025 765 ± 927 0.317 
IL1β     0.3 ± 0.1    0.3 ± 0.1 0.2 ± 0.1 0.519     0.1 ± 0.1 0.480          0.1 ± 0 0.034   0.1 ± 0.1 0.480 
IL2     0.3 ± 0.2    0.3 ± 0.2 0.3 ± 0.2 0.656  0.1 ± 0 0.058 0.1 ± 0 0.034   0.1 ± 0 0.034 
IL4     7.7 ± 1.0    7.3 ± 1.7 5.3 ± 2.2 0.779    2.2 ± 0.8 0.046   4.3 ± 2.3 0.317 5.1 ± 2.6 0.317 
IL6     8.0 ± 5.4    9.1 ± 5.9 7.8 ± 5.1 0.115   -0.3 ± 0.6 0.655    0.2 ± 0.4 0.655 0.7 ± 0.3 0.046 
IL7     4.0 ± 1.3    4.3 ± 1.5 2.5 ± 1.3 0.325    0.8 ± 0.6 0.034    1.2 ± 1.1 0.480 2.1 ± 1.6 0.157 
IL8     0.8 ± 0.3    0.7 ± 0.2 0.7 ± 0.3 0.122    0.1 ± 0.1 0.011    0.2 ± 0.1 0.002 0.2 ± 0.0 0.002 
IL10     3.9 ± 1.1    3.8 ± 1.1 3.8 ± 1.2 0.867    0.5 ± 0.1 0.008    1.0 ± 0.4 0.014 0.5 ± 0.2 0.059 
IL15     6.6 ± 5.6    8.3 ± 6.5 6.3 ± 5.8 0.449   -0.1 ± 0.3 0.655    -0.2 ± 0.5 0.655 0.4 ± 0.3 0.655 
LIF     9.7 ± 3.5    8.7 ± 3.2 4.9 ± 1.5 0.057   -1.6 ± 0.7 0.144        0 ± 0.9 0.893 2.6 ± 0.9 0.043 
Musclin     100 ± 13   108 ± 12     86 ± 9 0.066       -15 ± 9 0.059   -10 ± 8 0.705     12 ± 6 0.059 
Oncostatin     3.3 ± 0.9     3.4 ± 1.0  2.7 ± 0.9 0.061    -0.1 ± 0.4 0.527      0.2 ± 0.2 1.000   0.8 ± 0.4 0.206 
SPARC     56 ± 11     54 ± 10     42 ± 7 0.122  -16 ± 8 0.058      1 ± 6 0.527       9 ± 9 0.527 
TNFα     0.9 ± 0.1     0.9 ± 0.1  0.8 ± 0.1 0.926     0.4 ± 0.1 0.011     0.3 ± 0.1 0.011   0.3 ± 0.1 0.206 
            
Lactate (mmol/L) 2.7 ± 0.3 2.9 ± 0.3 4.0 ± 0.9 0.739  4.0 ± 0.7 0.016 3.7 ± 0.1 0.003 3.2 ± 0.6 0.005 
CK (U/L) 356.5 ± 86.2 344.2 ± 113.4 287.9 ± 62.9 0.441  28.8 ± 13.7 0.026 40.7 ± 12.6 0.003 20.2 ± 5.9 0.015 
Creatinine (mg/dL) 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.739  0.04 ± 0.01 0.003 0.04 ± 0.01 0.003 0.02 ± 0.02 0.137 








Supplemental Digital Content 1 (Figure). Individual data for patients’ main endpoints. 
Aerobic power, peak values 
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Strength test, bench press 
    
Maximal inspiratory muscle pressure 
 
 
Patients´ identification follows the same order as that in Table 1. Abbreviations: PImax, 
maximal inspiratory muscle pressure; PPO, peak power output; RCP, respiratory 
compensation point: VO2peak, peak oxygen uptake; VT, ventilatory threshold.  
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Supplemental Digital Content 2, Figure. Individual data for patients’ secondary endpoints. 
Functional tests indicative of ADLs 
   
DXA, lean mass 
    
      
DXA, fat  
     
DXA, bone 
      
 
 
Quality of life, SF-36 
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Patients´ identification follows the same order as that in Table 1. Abbreviations: ADL, 
activities of daily living; DXA, dual energy x-ray absorptiometry; SF-36, Short Form-36; 












































































































































































































































































































































































































Supplemental Digital Content 3, Table. Results of dual energy x-ray absorptiometry in 












   
DXA, lean mass 
   
Total lean mass (kg) 41.4 ± 2.8 50.4 ± 2.0  0.019  
Trunk lean mass (kg) 20.9 ± 1.3 25.5 ± 0.9  0.025  
Leg muscle mass (mean) (kg)   6.6 ± 5.3   8.2 ± 0.4  0.029 
Arm muscle mass (mean) (kg)   2.0 ± 0.2   2.6 ± 0.1  0.038  
  
   DXA, fat 
Total fat mass (kg) 24.3 ± 2.1 20.8 ± 1.4 0.198 
  
   DXA, bone 




0.75 ± 0.14 0.77 ± 0.07 0.849 
Femoral fracture risk (T-score) -1.2 ± 0.3 -0.8 ± 0.5 0.649 
 
Data are mean±SEM. Significant P-values are in bold and threshold P-value was set at 0.05. 
Abbreviation: DXA, dual energy x-ray absorptiometry. 
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